MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Running, not enrolling · Phase 3

Conditions studied: Unresectable Pleural Mesothelioma

In brief

This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.

Key facts

Study ID

NCT06097728

Run by

AstraZeneca

People needed

863

Starts

2023-11-09

Expected to finish

2028-11-16

Last updated by the study team

2026-07-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — Philadelphia, Pennsylvania, United States
• Research Site — Houston, Texas, United States
• Research Site — Fairfax, Virginia, United States
• Research Site — Chermside, Australia
• Research Site — Clayton, Australia
• Research Site — Melbourne, Australia
• Research Site — Nedlands, Australia
• Research Site — Westmead, Australia
• Research Site — Anderlecht, Belgium
• Research Site — Antwerp, Belgium
• Research Site — Ghent, Belgium
• Research Site — Hasselt, Belgium
• Research Site — Sint-Niklaas, Belgium
• Research Site — Barretos, Brazil
• Research Site — Fortaleza, Brazil
• Research Site — Porto Alegre, Brazil
• Research Site — Rio de Janeiro, Brazil
• Research Site — Santo André, Brazil
• Research Site — São Paulo, Brazil
• Research Site — Edmonton, Alberta, Canada
• Research Site — Ottawa, Ontario, Canada
• Research Site — Toronto, Ontario, Canada
• Research Site — Montreal, Quebec, Canada
• Research Site — Québec, Quebec, Canada
• Research Site — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.